Sanofi named a new chief scientific officer this week, part of a series of moves that the drug company has argued will establish it as being more focused on research and development than in the past.

Under the deal announced Friday, the Italian pharma will make an upfront payment of $825 million to Sanofi for global rights ...

Following the FDA's green light for a combo regimen of Sanofi’s Sarclisa in patients with newly diagnosed multiple myeloma last week, J&J has wasted little time hitting back with new data on its ...

The blockbuster Sanofi and Regeneron Pharmaceuticals drug Dupixent, already commercialized in several skin and lung disorders, has expanded its FDA-approval to chronic obstructive pulmonary ...

Also Read: FDA Approves Regeneron/Sanofi’s Blockbuster Dupixent For ... The deal will be funded by existing cash and new committed bank debt facilities. Net debt is expected to be approximately ...

Sept 27 (Reuters) - The U.S. Food and Drug Administration has approved Sanofi (SASY.PA), opens new tab and Regeneron's (REGN.O), opens new tab blockbuster drug Dupixent for patients with a chronic ...

A new $72 million award aims to double the U.S ... As part of the agreement, GSK, Sanofi, and CSL will produce extra bulk vaccine components tailored to the circulating strains of avian influenza.

Sanofi has asked bidders to revise their proposals for its consumer health unit, people with knowledge of the matter said, as it considers whether to seek a sale or listing of the business.

Sanofi will present 39 abstracts across approved and pipeline ... Additionally, we are excited to share new data from our pipeline, including results for amlitelimab showing the potential to provide ...

As Sanofi continues to clean out its medicine chest, Italy’s Recordati is getting in on the action. Recordati is floating $825 million upfront—plus another $250 million in potential commercial ...

There are 300,000 such people in the U.S., according to Regeneron and Sanofi, which jointly developed Dupixent.

As one of the first worldwide suppliers of the influenza vaccines, and now, with over 70 years of innovation in influenza ...